The CBD Science Group is a biopharmaceutical company that enables expedited access to treatment through a pragmatic, peer-reviewed clinical study from the real world. The aim is to rapidly deliver nationwide approved therapies to patients, with study protocols already developed and patient enrollment underway ahead of the launch date in the second quarter of 2022.

“We are excited and proud to have received this endorsement from the NCRI LWBC, which brings hope to millions of people with long-term cancer pain around the world. This partnership will move the CBD Science Group further towards our goal of realizing the benefits of cannabinoids. ”To meet this urgent need of suffering patients. We firmly believe in the opportunity our RWE study offers and look forward to working closely and deepening our relationship with the NCRI. “

Graeme McFarlane, Chief Commercial Officer, CBD Science Group.

The company has a prestigious clinical advisory board led by the group’s senior clinical advisor and former associate medical director of the NHS England Professor. appointed Mike Bewick along with other leading experts in the field, including Professor Sam Ahmedzai.

“Previous research on cancer-related pain has focused on people with advanced disease, however there is a large and rapidly growing population surviving many years on cancer-cancer treatments, an insurmountable barrier to productive and rewarding family living at all stages of cancer and friends. Unfortunately, current pain management options are largely ineffective or cause even more harmful side effects, so new research is urgently needed to find better therapies. I am excited to be actively involved in the CBD Science Group’s goal of providing an effective and safer medicinal cannabis solution find to alleviate the suffering of cancer-related pain patients. “

Prof Emeritus Sam Ahmedzai, Co-Chair of the NCRI Living With and Beyond Cancer Research Group

The NICE guidelines on medicinal cannabis found that to date there was no evidence of chronic pain in cancer patients, making research into the use of cannabinoids as alternative pain relievers very timely. Also, given the lack of evidence of effectiveness and significant evidence of the long-term harm from opioids, the National Institute for Health and Care Excellence (NICE) has advised against the use of opioids in people with chronic primary pain and is actively promoting research into alternatives Solutions.

In addition, the ongoing consequences of COVID-19 affect oncologists and clinicians across the UK. The UK has been reported to be experiencing an emerging cancer crisis after new numbers recently showed more than 300,000 people had missed checks for the disease since the pandemic began. Fear that more patients than ever will go untreated for their cancer and opioid prescriptions will continue to skyrocket as the NHS still fails to provide suitable alternatives.

There are an estimated 3 million cancer patients in the UK with 367,000 new diagnoses per year. From this population it has been shown that the prevalence of pain after curative treatment is 39.3%; 55.0% during cancer treatment; and 66.4% for advanced, metastatic, or terminal disease. With millions of patients going untreated for cancer-related pain, it is clear that there is an urgent need for evidence of cannabis-based drugs as an alternative to successful pain management.

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws. All information contained herein that is not historical in nature may constitute forward-looking information. The CBD Science Group undertakes no obligation to comment on any analysis, expectations, or statements by any third party with respect to the CBD Science Group, its securities, or financial or operating results (if any). While the CBD Science Group believes that the expectations reflected in any forward-looking statements in this press release are reasonable, such forward-looking statements are based on expectations, factors and assumptions about future events that may and may prove to be inaccurate subject to numerous risks and uncertainties, some of which are beyond the control of the CBD Science Group. Forward-looking information contained in this press release is expressly limited by this cautionary notice and is effective as of the date of this publication. CBD Science Group makes no intention and assumes no obligation or responsibility except as required by law to update or revise any forward-looking information, whether as a result of new information, future events or for any other reason.

Inquiry contact:
Barry Turley
E: [email protected]
T: +44 7734256318

SOURCE CBD Science Group PLC